Leptospirosis vaccine: who gets it and when

Leptospirosis is a zoonotic bacterial infection, outbreaks of which are associated with floods, warm fresh water, and contact with the urine of infected animals. The disease ranges from a mild fever to severe forms with damage to the liver, kidneys, and lungs. Vaccination of people can theoretically reduce the risk in high-exposure groups, but is not yet part of the routine schedules of most countries. [1]

Globally, the focus on prevention has shifted to rodent and household hazard control, personal protective equipment, and public awareness. Official outbreak response materials emphasize early diagnosis, antibiotic therapy, and sanitation measures over mass immunization. [2]

Some countries have local human bacterial vaccines. These are inactivated preparations, typically serogroup-specific, with limited duration of protection and greater reactogenicity compared to modern recombinant platforms. This is why they are used selectively among professional groups rather than in widespread programs. [3]

Human vaccines are generally unavailable to travelers and the general population. Prevention involves avoiding fresh water where it can be contaminated, protecting skin and eyes, and seeking medical attention early if a fever develops after water activities or working in flooded areas.

Where are human vaccines actually available?

Commercially available human vaccines are described in the literature for a limited number of countries and are used for occupational indications. The data are summarized in the table.

Table 1. Availability of human leptospirosis vaccines by country and typical indications

Country	Availability and status	Who is it indicated for?	Notes
France	There is a vaccine for high-risk groups	Sewage and waste disposal workers, farmers, livestock breeders	The institute's leaflet states that it is only available to highly exposed workers.
Japan	Limited availability through quarantine services and individual institutions	Workers at risk of aquatic exposure, according to local indications	A number of sources mention bivalent and tetravalent bacterins
China	Epidemiological immunization programs in endemic areas for risk groups	Contingents in hotspots, seasonal campaigns	Multivalent inactivated variants were used, protection is serogroup-specific
Cuba	The trivalent vaccine vax-SPIRAL was used in endemic areas	Risk groups and focal campaigns	Efficacy and pharmacovigilance reports, serogroup-specific protection
Most other countries	There is no vaccine for humans	-	Confirmed for Europe and the US: No human vaccine

The European Centre for Disease Control emphasizes that human vaccines are only available in a limited number of countries, are not universal, and are not suitable for widespread immunization of the population.

In the United States and most European countries, the human vaccine is not licensed. Non-immunological protective measures and, when indicated, short-term antibiotic prophylaxis are being considered as alternatives.

Who and when should consider immunization?

Immunization is important where it is available and where the risk is high. The main target groups are listed below.

Table 2. Risk-based logic for immunization appointments

Risk category	Examples of exhibitions	Recommendation in countries with available vaccine	Base
Very high risk	Long-term operation in wastewater, sewerage, waste sorting	Consider vaccination according to occupational indications	Official leaflets and career recommendations in France
High risk	Farmers, livestock breeders, slaughterhouses, rat-catchers	Consider vaccination according to occupational indications	Local regulations where the vaccine is available
Seasonal risk	Residents of endemic areas during the flood season	Focal and seasonal campaigns	Historical experience in China and Cuba
Short-term peak	Military exercises, rescue operations after floods	The vaccine is rarely available, and antibiotic prophylaxis is more often discussed.	International travel advisories and travel contingents

In countries without a licensed human vaccine, the focus of prevention shifts to antibacterial prophylaxis as indicated, personal protective equipment, and sanitary measures.

Composition, regimens and limitations of existing vaccines

Available human vaccines are inactivated bacterial preparations. They generate a primarily serogroup-specific antibody response, which poorly covers the diversity of circulating serovars, of which there are several hundred. [4]

The protection is short-term. The literature notes the need for revaccination, as well as a higher incidence of local reactions compared to current platforms. This is a key limitation for mass programs. [5]

Administration schedules may vary by country and drug. Descriptions include a primary series followed by booster doses at limited intervals to maintain antibody titers. Specific schedules are determined by local regulations. [6]

Table 3. What is important to know about available bacterial vaccines

Parameter	Typical characteristics	Comment
Platform	Inactivated bacterial suspensions	Historically the most accessible format
Protection spectrum	Serogroup-specific	Weak cross-protection between serogroups
Duration	Typically up to one or two years	Booster doses are required to maintain protection.
Reactogenicity	Local reactions, fever	Limits widespread use

What is known about effectiveness?

There are few robust, high-quality randomized trials. The Cuban trivalent vaccine has been reported to reduce disease incidence in outbreaks and to be approximately 78% effective against target serogroups, with a good safety profile. This effect is context-specific and does not imply universal protection against all serotypes. [7]

France has reported experience using a monovalent vaccine strain corresponding to the dominant serogroup, with acceptable immunogenicity and the need for boosters to maintain antibody levels. This approach is only effective with a stable serogroup profile. [8]

In Japan and China, efficacy is assessed primarily in programs for high-risk groups, with mixed data. Systematic reviews emphasize the short duration of immunity and the dependence of the effect on serogroup matching between the vaccine and circulating strains. [9]

Table 4. Summary of performance benchmarks in publications

Drug or country	Evaluation of effectiveness	Context
Cuba, vax-SPIRAL	About 78% against target serogroups	Focal programs among risk groups
France, monovalent drug	Immunogenicity confirmed, boosters needed	Professional contingents, dominant serogroup
Japan, multivalent variants	Data is limited, historical series	Professional indications
China, multivalent variants	Effect in endemic areas with coincidence of serogroups	Focal campaigns

Safety, contraindications and interactions with other measures

Inactivated bacterial vaccines are more likely to cause local reactions, including transient fever and malaise. Pharmacovigilance studies, including causal relationships and profiles of common adverse events, have been described. Severe complications are rare. [10]

Standard contraindications include severe allergic reactions to components, acute febrile conditions, and delays in use until chronic diseases stabilize. The decision is made by a physician based on the benefit and risk for the individual. [11]

It is important to understand that vaccination does not replace the need for skin and eye protection, hygiene practices when working with water and soil, and rodent control. A combination of measures remains the basic standard. [12]

Table 5. Common adverse events and what to do about them

Adverse event	How often?	What to do
Pain and redness at the injection site	Often	Cold, oral analgesics if needed
Malaise and low-grade fever	Sometimes	Drinking, rest, symptomatic treatment
Severe fever	Rarely	Consult a doctor to rule out other causes
Allergic reaction	Very rarely	Urgent medical care, contraindication for repetition

Antibiotic prophylaxis: When it is appropriate and how it relates to vaccination

In the absence of a licensed human vaccine, many countries rely on short-term antibiotic prophylaxis for adults with very high and short-term exposure risk. Doxycycline has been studied best, with a regimen of 200 milligrams once weekly, beginning one to two days before exposure and continuing for the entire risk period. The evidence base is mixed, and some studies have shown an effect on clinical cases, although the risk of nausea increases. Use is limited to high-risk scenarios. [13]

This prophylaxis is not suitable for pregnant women and has age restrictions. There is little evidence for children. The use of alternatives is being discussed, but there is insufficient convincing data. A doctor makes the decision based on individual benefits and risks. [14]

Table 6. Antibiotic prophylaxis of leptospirosis: comparison of regimens and restrictions

Scheme	Who is it for?	Limitations and risks	Comment
Doxycycline 200 mg weekly during the risk period	Adults at short-term high risk	Nausea, photosensitivity, contraindicated in pregnant women	Considered as an option in travel medicine reference books
Doxycycline single dose or short courses after contact	In individual national flood algorithms	The data is heterogeneous, the solution is individual	Used in some temporary recommendations

Animal Vaccination and the One Health Strategy

Widespread use of vaccines in dogs and farm animals reduces clinical cases in animals and indirectly impacts the risk to humans, although it does not always prevent renal bacterial excretion. This approach is relevant to veterinary practice and an important part of a multisectoral response.

Veterinary guidelines discuss the need for immunization in dogs based on local risk. In some countries, the vaccine is considered recommended for most dogs, while in others, it is used selectively. This reflects differences in circulating serogroups and epidemiological conditions. [15]

Table 7. Animal vaccination and impact on human risk

Animals	Why vaccinate?	Restrictions	Impact on humans
Dogs	Reduction in clinical cases	It is possible to remove bacteria in the urine even with vaccination	Reducing sources of exposure
Cattle and pigs	Reduction of reproductive losses	Efficiency depends on serovar compatibility	Reducing environmental pollution

What's in development and what to expect in the future

International groups are actively testing new platforms: subunit vaccines based on outer membrane proteins, live attenuated candidates, and multicomponent constructs. The goal is to achieve cross-protection against multiple serovars and longer-lasting immunity with improved tolerability. This is currently in the exploratory phase. [16]

Peer-reviewed reviews highlight that the key issue is the serovar specificity of current antigens and the dependence of protection on lipopolysaccharides. Conserved virulence proteins are promising, but clinical data for humans are still limited. [17]

Table 8. Directions of vaccine research

Approach	Potential benefits	Current status
Subunit protein antigens	Security, chances of cross-protection	Preclinical and early clinical stages
Live attenuated	A vibrant immune response	Security issues require consideration.
Multi-epitope constructs	Theoretically wide range	Early research

Practical algorithm of actions

If you are in a country without a licensed human vaccine:
a) assess the risk of exposure, b) use protective gloves, boots, and goggles when in contact with fresh water and soil, c) discuss with your doctor the need for short-term antibiotic prophylaxis for very high and short-term risk, d) if fever develops after contact with fresh water, seek immediate medical attention and report exposure.

If you belong to an occupational risk group in a country where the vaccine is available:
Discuss occupational vaccination with your doctor, taking into account local serogroups, revaccination schedules, and your medical risk factors. Vaccination does not replace personal protection and sanitary measures. [18]

During outbreaks and floods:
Follow local health authority guidance. Mass vaccination of people is generally not recommended. Sanitary measures are taken, and antibiotic prophylaxis may be considered for extremely high-risk populations. [19]

Key findings

1. There is no universal and long-lasting human vaccine. Available options are administered locally to narrow groups and protect primarily against specific serogroups. [20]
2. In most countries, the vaccine is not licensed for use in humans. The focus is on hygiene, protective equipment, and early diagnosis, as well as short-term antibiotic prophylaxis in adults at very high and short-term risk. [21]
3. Promising platforms are under development, but scientific and practical barriers remain to widespread adoption. [22]